Please login to the form below

Not currently logged in
Email:
Password:

Cristal Therapeutics names chief medical officer

Edwin Klumper joins from contract research firm SMS-oncology 

Cristal Therapeutics, a privately-held life sciences company based in The Netherlands, has appointed Edwin Klumper as its chief medical officer.

In his new role, Klumper will be responsible for the clinical strategy and development of Cristal Therapeutics' range of nanomedicines.

He joins the pharmaceutical firm from SMS-oncology, a CRO specialising in clinical development studies in oncology, which he co-founded in 2007.

Klumper served as its chief medical officer until 2013 when he became the organisation's interim chief executive.

Prior to this, Klumper served as vice president, marketing and sales Europe at Nabi Biopharmaceuticals and business unit director for The Netherlands at Amgen.

He also brings experience from ASTA Medica and start-up Yew Tree Pharmaceuticals where he served as its medical director.

Joost Holthuis, Cristal Therapeutics' chief executive officer, said: “We are extremely fortunate to have Edwin joining our leadership team.

“Edwin will no doubt contribute to the already firm nanomedicine programme of CriPec docetaxel, as well as help up move forward in our efforts to develop novel proprietary nanomedicines.”

4th May 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics